# Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections

> **NCT01102387** · PHASE2 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 137 (actual)

## Conditions studied

- Candidiasis

## Interventions

- **DRUG:** LAS41003
- **DRUG:** LAS189962
- **DRUG:** LAS189961

## Key facts

- **NCT ID:** NCT01102387
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2012-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01102387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01102387, "Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01102387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*